LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Recruiting now
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies
Key facts
- Study ID
- NCT02511288
- Run by
- Centre Leon Berard
- People needed
- 900
- Starts
- 2015-07-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2024-08-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
- Inclusion at the time of diagnostic
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
You may not qualify if…
- Patients treated before their liquid biopsy
- COHORT 2 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
- Inclusion at the time of diagnosis
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
- COHORT 3 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
- Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
- Exclusion criteria
- Initiation of immunotherpy before their liquid biopsy
Where it is running
- Centre Léon Bérard — Lyon, France (enrolling)
- CH Fleyriat — Bourg-en-Bresse, France
- Hôpital Louis Pradel — Bron, France
- CHU Grenoble Alpes — Grenoble, France
- CHRU de Saint-Etienne — Saint-Priest-en-Jarez, France
- Institut de Cancérologie Lucien Neuwirth — Saint-Priest-en-Jarez, France
- Centre Hospitalier Annecy Genevois — Annecy, France
- Hôpital Nord Ouest — Villefranche-sur-Saône, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.